GlassScriptPhysician profile
David I Fudman
NPI 1588956213
$29,227.53
in general payments reported to CMS, 2019-2025
10 companies · $10K in 2025
The $10K reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $3,600 · 2021: $39.47 · 2022: $2,574 · 2023: $2,331 · 2024: $10K · 2025: $10K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $19K · Travel and Lodging: $2,245 · Education: $1,244 · Food and Beverage: $667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $18,857.50 |
| Travel and Lodging | $2,245.16 |
| Education | $1,244.24 |
| Food and Beverage | $666.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $12,285.10 | 2023-2024 | Tremfya, Stelara |
| Lilly USA, LLC | $10,346.30 | 2025 | Omvoh |
| Pfizer INC. | $3,627.68 | 2020-2022 | |
| Fresenius Kabi USA, LLC | $2,440.00 | 2022 | |
| Janssen Biotech, INC. | $127.42 | 2022-2023 | Stelara |
| Celgene Corporation | $120.76 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $118.64 | 2025 | Entyvio |
| Erbe USA INC | $80.77 | 2023 | Erbe Vio3 Apc3 |
| Abbvie INC. | $60.91 | 2021-2025 | |
| Dynavax Technologies Corporation | $19.95 | 2025 | Heplisav-B |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fudman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.